FYI: Loncar Investments, along with Exchange Traded Concepts, is bringing to market today a new ETF that sets out to capture the growth in China’s emerging biopharmaceutical sector.
The Loncar China BioPharma Index ETF (CHNA) isn’t a one-of-a-kind strategy per se, but then again, it almost is. Brad Loncar, the biotech investor behind the $56 million Loncar Cancer Immunotherapy ETF (CNCR), says CHNA is coming to market right as China’s biotech sector is about to take off, and until now, ETF investors have had little access on that story.
CHNA lists on the Nasdaq stock market.
Regards,
Ted
https://www.etf.com/sections/daily-etf-watch/china-biotech-etf-launches
